Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
"Loading Zone"
Like I said, Friday was the leading zone.
Back at low side of the .65 to .80 channel. No brainer loading zone here.
Zacks had a strong sell rating on June 22, 2017. They're awesome if you don't like to make money.
Been watching for your fall into the .20's, for what, a year now? Getting nervous with this support here, eh Harry?
.20's. LOL.
Adam hasn't talked about AVEO since before the trial ended. Almost a year since he put his 2 cents in. Mentioning him is irrelevant. God your arguments are lame.
It's just you and me pal.
Post a link. Don't be lazy. I always post links. Why don't you?
Novartis paid $15M to keep AV-380 off the street. And then they had to pay millions for doing it.
Nice try.
$5 by Christmas. No soup for you!
More old news. August is coming like a freight train. LOL
it's a Tivo-3 mature data deal. Was stated on initial EU approval. Old news Harry
Please cite references that "it is not performing as expected" in the EU. It can't be fast-tracked by the FDA until an NDA is submitted. The FDA suggested not submitting the NDA until the data is mature, which will be in Q4. It's so easy to call the lies out.
Tivo combinations will be first line. And on its own, Tivo will help patients whose prior drugs didn't work. "The drug works." And it is horrible to post lies about something improving suffering people's lives.
Tivozanib significantly improves PFS and ORR compared to sorafenib in patients with treatment-refractory advanced RCC. Tivozanib was superior in patients previously treated with checkpoint inhibitors as well as two VEGFR-TKIs. Responses with tivozanib were more durable than sorafenib. Tivozanib was well tolerated with hypertension as the most common adverse event. Lower rates of hand foot syndrome, diarrhea, and rash were observed for tivozanib compared to sorafenib. OS data are immature with final analysis pending. It's clear that Q4 is worth waiting for.
Horrible people post lies about companies that make lives better for people suffering with cancer. Horrible people.
https://www.macmillan.org.uk/information-and-support/kidney-renal-cancer/treating/targeted-biological-therapies/targeted-biological-therapies-explained/targeted-therapies-kidney-cancer.html
The trial's already met its primary endpoint. Waiting on mature data. Easy $3 in Q4, if not much higher.
New president and CEO? How's that going to effect the short brigade? Did you see that coming Harry? LOL
Insiders buying today and reverse split is off the table. Buyout imminent pending Q4 data readout.Ignore the chaff. You'll get yourself some AVEO under $1 if your light's on.
AVEO short sellers may need these shorts soon: https://workingperson.com/workwear-1/flame-resistant-clothing/flame-resistant-underwear.html
Company is sold pending O/S data in Q4. A surety of $3 on data readout, then $7-$9 on buyout. It's happening like sunrises and sunsets happen.
AVEO is already sold pending O/S data, IMO. Ask yourself why an acquirer would go through all of that if confidence is not high. $7 to $9 coming for those that have patience.
Ignore the false narrative. Easy $3 after data readout in Q4. Swing trade this between .65 and .80 until then. No R/S coming, IMO. They asked for it just in case of denied request for a notice extension which they'll likely receive with incoming trial data readout. Horrible people post lies about companies making cancer patients' lives better. Horrible people.
Trade AVEO between .65 and .80 for easy money as we wait for $3+ in Q4. It happened 2 years ago and the re-run's playing now.
Where's .25? Where's .50? Where's bankruptcy? Wrong, wrong, and wrong. Trade this for profits between .65 and .80, as it's not leaving that channel until it explodes past $3 in Q4
Not according to the patients being successfully treated in Europe.
https://community.macmillan.org.uk/cancer_types/kidney-cancer/f/kidney-cancer-forum/181210/pazopanib-votrient?Page=1#1343573
Let's attack a company that's selling a drug that improves people's lives who are suffering with traumatic kidney cancer. Nice.
From the MacMillan Cancer Support Blog in Scotland. Check out entries from May 17 and June 7(yesterday). This is actually from a Pazopanib thread. Tivo doesn't seem like "junk science" to cancer patients who are taking it. On the contrary. I wonder why people like to spread lies on stock message boards about a drug that is shrinking tumors and making patients' lives better. Pathetic souls.
https://community.macmillan.org.uk/cancer_types/kidney-cancer/f/kidney-cancer-forum/181210/pazopanib-votrient?Page=1#1343573
Wrong again. Green day. Doesn't seem to want to drop like you keep saying it does.
Hmmm. It went up over 30% last Friday. It'd be nice if you could post something that's right.
Never going to .25, ever. High .50's maybe.
This erratic trading will be here until Q4. Buy in the .60's, sell in the .80's. Wash. Rinse. Repeat.
.25 right Harry? And then BK. You've been saying the same thing for years. No buyers? LOL
Down less than a penny today after a 35% run Friday. Some posts on this board don't make any sense.
LOL. You have great timing.
4 minutes. I smell the cotton igniting
17 minutes until your pain resumes. LOL.